SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- An international panel of critical care experts will discuss how new biomarkers for risk assessment of acute kidney injury (AKI) could affect care of critically ill patients at a symposium being held in conjunction with the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress in San Francisco, Calif. Astute Medical, Inc. is sponsoring the event "Early AKI Assessment: Are New Biomarkers Rising to the Challenge" which will take place on Friday, January 10, 2014 at 6:30 p.m.
Conference attendees interested in participating can visit AKIAssessment.com to register online. Event participants and others can follow the live event via Twitter @ACuteKidneyMan.
Program highlights include:
- Dr. John Kellum of the University of Pittsburgh Medical Center, who will discuss the pathogenesis of AKI;
- Dr. Kianoush Kashani of the Mayo Clinic, who will present the latest research highlighting two new biomarkers found to be highly accurate in the risk assessment of AKI and superior to current methods;
- Dr. Kyle Gunnerson of the University of Michigan Health System, who will delve into practical uses of biomarkers in the management of patients at risk of developing AKI; and
- Dr. Azra Bihorac of the University of Florida, who will discuss the incidence, outcomes and implications of periopertative AKI and how prevalence and risk of postoperative AKI is underestimated by the National Surgical Quality Improvement Program.
Acute kidney injury is a complex and increasingly prevalent condition associated with high mortality and morbidity in critically ill patients. Failure to recognize and manage AKI in the early stages can lead to devastating outcomes for patients and increased costs to the healthcare system. Because AKI develops quickly (over the course of hours) and current tools available to physicians for risk assessment are inadequate, the condition often goes undetected until it is too late to help the patient.
Plan to visit Astute Medical's booth #621 during the SCCM 43rd Critical Care Congress. Not attending the SCCM Congress? For more information stay connected with Astute Medical at AstuteMedical.com or via:
About Astute Medical, Inc.
Named by the Wall Street Journal as one of the Top 10 Healthcare Start-Ups of 2012, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For additional information, please visit AstuteMedical.com
The NephroCheck® Test and the Astute140® Meter are not available for sale in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectual-property. PN:0240 RevA 2014/01/02.
SOURCE Astute Medical, Inc.